Cardiology Stem Cells Market

Cardiology Stem Cells Market (Application: Heart Failure, Myocardial Infarction, Critical Limb Ischemia, and Others; Source: Autologous and Allogenic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Cardiology Stem Cells Market Outlook 2031

  • The global industry was valued at US$ 2.6 Bn in 2022
  • It is projected to grow at a CAGR of 7.4% from 2023 to 2031 and reach more than US$ 5.1 Bn by the end of 2031

Analysts’ Viewpoint

Launch of new and innovative therapies for treatment of heart diseases is driving the global cardiology stem cells market. Advancements in stem cell research and surge in incidence of cardiovascular diseases are expected to propel market expansion in the next few years. Furthermore, increase in healthcare spending and rise in awareness about the benefits of early detection and treatment are expected to bolster market development in the near future.

Increase in adoption of stem cell technology in emerging economies, surge in investment in stem cell research, and rise in number of clinical trials focused on cardiac stem cell therapies offer lucrative opportunities for market players. Companies are focusing on introduction of new products with advanced technology for the treatment cardiovascular diseases.

Cardiology Stem Cells Market

Cardiology Stem Cells Market Introduction

Cardiac stem cell therapy refers to a specialized branch of regenerative medicine that focuses on using stem cells to repair and regenerate damaged heart tissue. Stem cells are undifferentiated cells that have the potential to develop into various types of cells in the body. In cardiology, stem cells can be used to replace damaged heart muscle cells, promote the growth of new blood vessels, and improve overall heart function. Cardiac stem cells can be obtained from various sources such as bone marrow, adipose tissue, and embryonic or induced pluripotent stem cells.

Several clinical trials have been conducted to evaluate the safety and efficacy of cardiovascular stem cell therapies, and results have shown promising outcomes in improving heart function and reducing symptoms in patients with heart disease.

Stem cell therapy aims to deliver the best cells to the best location at the best time for the longest possible period in order to obtain the best patient outcomes. Metrics including ejection fraction, mixed venous oxygen saturation (MVO2), objective measurements of ischemia, and mortality are used to gauge improved outcomes for doctors. Patients express their expectations of results in more ethereal words, such as cessation of chest pain, diminution of breathlessness, improvement in exercise tolerance, and extension of life. Regardless of the criteria, stem cell therapy has the potential to improve patient outcomes and is getting closer to becoming a reality.

Advancement in Stem Cell Research Driving Global Cardiology Stem Cells Market Share

Advances in stem cell research have led to a better understanding of stem cells and their potential applications in regenerative medicine, including cardiology stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to become pluripotent, meaning they have the ability to differentiate into any cell type in the body. This technology has the potential to overcome some of the ethical concerns associated with embryonic stem cells and allows for the creation of patient-specific stem cell lines, which can be used for personalized medicine.

CRISPR/Cas9 gene editing is a powerful gene editing tool that can be used to manipulate the genetic material of stem cells to correct disease-causing mutations or introduce beneficial traits. This technology has the potential to revolutionize the development of stem cell therapies and personalized medicine. Organoids are three-dimensional structures that mimic the complex organization and function of organs in the body. Tissue engineering involves the creation of functional tissues using stem cells and scaffolds. These technologies have the potential to revolutionize the development of personalized therapies and improve our understanding of human physiology and disease. Advances in biomaterials and microscale engineering have led to the development of new delivery methods for stem cell therapies.

New and Innovative Therapies to Treat Heart Disease

The need for new and innovative therapies to treat heart disease is a major driver of the global cardiology stem cells market growth. Heart disease is a leading cause of death globally. Current treatments such as medications, surgery, and lifestyle modifications have limitations and are not effective for all patients.

Cardiology stem cell therapy offers a potential new treatment option for heart disease. This therapy involves the usage of stem cells to repair damaged heart tissue, promote angiogenesis, and improve overall heart function. Clinical trials have shown promising results with cardiology stem cell therapies, providing evidence of their safety and effectiveness in improving heart function and reducing symptoms in patients with heart disease.

The potential benefits of cardiology stem cell therapy, combined with the need for new and innovative therapies for heart disease, are driving market progress.

Usage of Adult Stem Cells Reduces the Risk of Rejection and Lowers Risk of Complications

In terms of type of cell, the adult stem cells segment dominated the global cardiology stem cells market in 2022. Adult stem cells can be easily harvested from a patient's own body, eliminating the need for a donor and reducing the risk of rejection. Moreover, these have a lower risk of forming tumors compared to embryonic stem cells. This reduces the risk of complications associated with cell-based therapies.

Regeneration and Repair of Damaged Heart Tissue in Heart Failure Patients

Based on application, the global cardiology stem cells market has been segregated into heart failure, myocardial infarction, critical limb ischemia, and others. The heart failure segment accounted for major share of the global market in 2022. Heart failure is a medical condition that occurs when the heart is unable to pump enough blood to meet the body's needs. This could happen when the heart becomes weak or damaged, and can lead to various symptoms, including shortness of breath, fatigue, swelling in the legs, and difficulty exercising. Cardiology stem cells to promote the regeneration and repair of damaged heart tissue.

Patient Preference for Stem Cell Therapy at Hospitals

Based on end-user, the global cardiology stem cells market has been divided into pharmaceutical and biotechnology companies, hospitals & cell banks, and academic & research institutes. The hospitals segment accounted for the largest share of the global market in 2022. Large number of heart patients prefer to have stem cell therapy at hospitals.

Regional Outlook of Global Cardiology Stem Cells Market

North America accounted for major share of the global market in 2021. The market in the region is likely to expand at a high CAGR from 2022 to 2031. The region has a number of prominent stem cell research centers and institutes, as well as companies that are working on developing stem cell-based therapies.

As per cardiology stem cells market analysis, Asia Pacific dominated the global industry in 2022. The market in the region is likely to grow at a rapid pace from 2023 to 2031. Asia Pacific is a major market for stem cell research and therapy, with several countries investing in research & development of stem cell therapies. Japan, South Korea, China, and Singapore are some of the countries in Asia Pacific with significant progress in stem cell research and development. Japan, for instance, has a well-established regulatory framework for stem cell research, and several clinical trials are currently underway to test the safety and efficacy of stem cell therapies for a range of diseases.

Analysis of Key Players

The global cardiology stem cells market is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and merger & acquisition are the key strategies adopted by the key players. Leading players in the global market are Astellas Pharma Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited, Cytori Therapeutics, Inc., Bio Cardia, Inc., and Lisata Therapeutics.

Key Developments in Global Cardiology Stem Cells Market

  • In December 2022, Bio Cardia, Inc., an inventor of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application to initiate a first-in-human phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure
  • In May 2021, Kalyagen, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), announced the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient with Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating endogenous stem cell mobilization (ESCM).

Each of these players has been profiled in the cardiology stem cells market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Cardiology Stem Cells Market Snapshot

Attribute

Detail

Size in 2022

US$ 2.6 Bn

Forecast (Value) in 2031

US$ 5.1 Bn

Growth Rate (CAGR)

7.4%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Type of Cell
    • Embryonic Stem Cells
    • Adult Stem Cells
    • Induced Pluripotent Stem Cells
    • Cord Blood Stem Cells and Amniotic Fluid Stem Cells
  • Application
    • Heart Failure
    • Myocardial Infarction
    • Critical Limb Ischemia
    • Others
  • Source
    • Autologous
    • Allogenic
  • End-user
    • Pharmaceutical & Biotechnology Companies
    • Hospitals & Cell Banks
    • Academic & Research Institutes

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Astellas Pharma, Inc.
  • STEMCELL Technologies
  • Cellular Engineering Technologies
  • BioTimes, Inc.
  • Takara Bio, Inc.
  • U.S. Stem Cell, Inc.
  • BrainStorm Cell Limited.
  • Cytori Therapeutics, Inc.
  • Lisata Therapeutics
  • Bio Cardia, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cardiology stem cells market in 2022?

The global industry was valued at US$ 2.6 Bn in 2022

How big will cardiology stem cells industry be in 2031?

It is projected to reach more than US$ 5.1 Bn by 2031

What will be the CAGR of the cardiology stem cells business during the forecast period?

The CAGR is anticipated to be 7.4% from 2023 to 2031.

Which are the prominent factors fueling the demand of cardiology stem cells?

Advancements in stem cell research and new & innovative therapies to treat heart diseases are driving the global cardiology stem cells market

Which region will to account for major share?

North America is expected to account for the largest share of the global market during the forecast period.

Who are the prominent cardiology stem cells players?

Astellas Pharma, Inc., STEMCELL Technologies, Cellular Engineering Technologies, BioTimes, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Limited, Cytori Therapeutics, Inc., Bio Cardia, Inc., and Lisata Therapeutics are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cardiology Stem Cells Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Bn)

    5. Key Insights

        5.1. Key Mergers & Acquisitions

        5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

        5.3. Pipeline Analysis

        5.4. Disease Prevalence & Incidence Rate globally with key countries

    6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type of Cell, 2017-2031

            6.3.1. Embryonic Stem Cells

            6.3.2. Adult Stem Cells

            6.3.3. Induced Pluripotent Stem Cells

            6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        6.4. Market Attractiveness Analysis, by Type of Cell

    7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017-2031

            7.3.1. Heart Failure

            7.3.2. Myocardial Infarction

            7.3.3. Critical Limb Ischemia

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Application

    8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Source, 2017-2031

            8.3.1. Autologous

            8.3.2. Allogenic

        8.4. Market Attractiveness Analysis, by Source

    9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by End-user, 2017-2031

            9.3.1. Pharmaceutical & Biotechnology Companies

            9.3.2. Hospitals & Cell Banks

            9.3.3. Academic & Research Institutes

        9.4. Market Attractiveness Analysis, by End-user

    10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Cardiology Stem Cells Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type of Cell, 2017-2031

            11.2.1. Embryonic Stem Cells

            11.2.2. Adult Stem Cells

            11.2.3. Induced Pluripotent Stem Cells

            11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        11.3. Market Value Forecast, by Application, 2017-2031

            11.3.1. Heart Failure

            11.3.2. Myocardial Infarction

            11.3.3. Critical Limb Ischemia

            11.3.4. Others

        11.4. Market Value Forecast, by Source, 2017-2031

            11.4.1. Autologous

            11.4.2. Allogenic

        11.5. Market Value Forecast, by End-user, 2017-2031

            11.5.1. Pharmaceutical & Biotechnology Companies

            11.5.2. Hospitals & Cell Banks

            11.5.3. Academic & Research Institutes

        11.6. Market Value Forecast, by Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Type of Cell

            11.7.2. By Application

            11.7.3. By Source

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Cardiology Stem Cells Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type of Cell, 2017-2031

            12.2.1. Embryonic Stem Cells

            12.2.2. Adult Stem Cells

            12.2.3. Induced Pluripotent Stem Cells

            12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        12.3. Market Value Forecast, by Application, 2017-2031

            12.3.1. Heart Failure

            12.3.2. Myocardial Infarction

            12.3.3. Critical Limb Ischemia

            12.3.4. Others

        12.4. Market Value Forecast, by Source, 2017-2031

            12.4.1. Autologous

            12.4.2. Allogenic

        12.5. Market Value Forecast, by End-user, 2017-2031

            12.5.1. Pharmaceutical & Biotechnology Companies

            12.5.2. Hospitals & Cell Banks

            12.5.3. Academic & Research Institutes

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Type of Cell

            12.7.2. By Application

            12.7.3. By Source

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type of Cell, 2017-2031

            13.2.1. Embryonic Stem Cells

            13.2.2. Adult Stem Cells

            13.2.3. Induced Pluripotent Stem Cells

            13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        13.3. Market Value Forecast, by Application, 2017-2031

            13.3.1. Heart Failure

            13.3.2. Myocardial Infarction

            13.3.3. Critical Limb Ischemia

            13.3.4. Others

        13.4. Market Value Forecast, by Source, 2017-2031

            13.4.1. Autologous

            13.4.2. Allogenic

        13.5. Market Value Forecast, by End-user, 2017-2031

            13.5.1. Pharmaceutical & Biotechnology Companies

            13.5.2. Hospitals & Cell Banks

            13.5.3. Academic & Research Institutes

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. Japan

            13.6.2. China

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Type of Cell

            13.7.2. By Application

            13.7.3. By Source

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Cardiology Stem Cells Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type of Cell, 2017-2031

            14.2.1. Embryonic Stem Cells

            14.2.2. Adult Stem Cells

            14.2.3. Induced Pluripotent Stem Cells

            14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        14.3. Market Value Forecast, by Application, 2017-2031

            14.3.1. Heart Failure

            14.3.2. Myocardial Infarction

            14.3.3. Critical Limb Ischemia

            14.3.4. Others

        14.4. Market Value Forecast, by Source, 2017-2031

            14.4.1. Autologous

            14.4.2. Allogenic

        14.5. Market Value Forecast, by End-user, 2017-2031

            14.5.1. Pharmaceutical & Biotechnology Companies

            14.5.2. Hospitals & Cell Banks

            14.5.3. Academic & Research Institutes

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Type of Cell

            14.7.2. By Application

            14.7.3. By Source

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Type of Cell, 2017-2031

            15.2.1. Embryonic Stem Cells

            15.2.2. Adult Stem Cells

            15.2.3. Induced Pluripotent Stem Cells

            15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells

        15.3. Market Value Forecast, by Application, 2017-2031

            15.3.1. Heart Failure

            15.3.2. Myocardial Infarction

            15.3.3. Critical Limb Ischemia

            15.3.4. Others

        15.4. Market Value Forecast, by Source, 2017-2031

            15.4.1. Autologous

            15.4.2. Allogenic

        15.5. Market Value Forecast, by End-user, 2017-2031

            15.5.1. Pharmaceutical & Biotechnology Companies

            15.5.2. Hospitals & Cell Banks

            15.5.3. Academic & Research Institutes

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Type of Cell

            15.7.2. By Application

            15.7.3. By Source

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (By Tier and Size of companies)

        16.2. Market Share Analysis By Company (2022)

        16.3. Company Profiles

            16.3.1. Astellas Pharma, Inc.

                16.3.1.1. Company Overview

                16.3.1.2. Product Portfolio

                16.3.1.3. SWOT Analysis

                16.3.1.4. Strategic Overview

            16.3.2. STEMCELL Technologies

                16.3.2.1. Company Overview

                16.3.2.2. Product Portfolio

                16.3.2.3. SWOT Analysis

                16.3.2.4. Strategic Overview

            16.3.3. Cellular Engineering Technologies

                16.3.3.1. Company Overview

                16.3.3.2. Product Portfolio

                16.3.3.3. SWOT Analysis

                16.3.3.4. Strategic Overview

            16.3.4. BioTimes, Inc.

                16.3.4.1. Company Overview

                16.3.4.2. Product Portfolio

                16.3.4.3. SWOT Analysis

                16.3.4.4. Strategic Overview

            16.3.5. Takara Bio, Inc.

                16.3.5.1. Company Overview

                16.3.5.2. Product Portfolio

                16.3.5.3. SWOT Analysis

                16.3.5.4. Strategic Overview

            16.3.6. U.S. Stem Cell, Inc.

                16.3.6.1. Company Overview

                16.3.6.2. Product Portfolio

                16.3.6.3. SWOT Analysis

                16.3.6.4. Strategic Overview

            16.3.7. BrainStorm Cell Limited

                16.3.7.1. Company Overview

                16.3.7.2. Product Portfolio

                16.3.7.3. SWOT Analysis

                16.3.7.4. Strategic Overview

            16.3.8. Cytori Therapeutics, Inc.

                16.3.8.1. Company Overview

                16.3.8.2. Product Portfolio

                16.3.8.3. SWOT Analysis

                16.3.8.4. Strategic Overview

            16.3.9. Bio Cardia, Inc.

                16.3.9.1. Company Overview

                16.3.9.2. Product Portfolio

                16.3.9.3. SWOT Analysis

                16.3.9.4. Strategic Overview

    List of Tables

    Table 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031

    Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031

    Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

    Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

    Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

    Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 02: Global Cardiology Stem Cells Market Value Share, by Type of Cell, 2022

    Figure 03: Global Cardiology Stem Cells Market Value Share, by Application, 2022

    Figure 04: Global Cardiology Stem Cells Market Value Share, by Source, 2022

    Figure 05: Global Cardiology Stem Cells Market Value Share, by End-user, 2022

    Figure 06 Global Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 07: Global Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 08: Global Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 09: Global Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 10: Global Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 11: Global Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 12: Global Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 13: Global Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 14: Global Cardiology Stem Cells Market Value Share Analysis, by Region, 2022 and 2031

    Figure 15: Global Cardiology Stem Cells Market Attractiveness Analysis, by Region, 2023-2031

    Figure 16: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 17: North America Cardiology Stem Cells Market Value Share Analysis, by Country, 2022 and 2031

    Figure 18: North America Cardiology Stem Cells Market Attractiveness Analysis, by Country, 2023-2031 

    Figure 19: North America Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 20: North America Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 21: North America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 22: North America Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 23: North America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 24: North America Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 25: North America Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 26: North America Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 27: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 28: Europe Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 29: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 30: Europe Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 31: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 32: Europe Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 33: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 34: Europe Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 35: Europe Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 36: Europe Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 37: Europe Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 38: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 39: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 40: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 41: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 42: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 43: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 44: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 45: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 46: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 47: Asia Pacific Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 48: Asia Pacific Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 49: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 50: Latin America Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

    Figure 51: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

    Figure 52: Latin America Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 53: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 54: Latin America Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 55: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 56: Latin America Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 57: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 58: Latin America Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 59: Latin America Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 60: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, 2017–2031

    Figure 61: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

    Figure 62: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

    Figure 63: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Type of Cell, 2022 and 2031

    Figure 64: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Type of Cell, 2023-2031

    Figure 65: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Application, 2022 and 2031

    Figure 66: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Application, 2023-2031

    Figure 67: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by Source, 2022 and 2031

    Figure 68: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by Source, 2023-2031

    Figure 69: Middle East & Africa Cardiology Stem Cells Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 70: Middle East & Africa Cardiology Stem Cells Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 71: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved